Tyra Biosciences
Tyra Biosciences Inc is an American clinical-stage biopharmaceutical enterprise headquartered in Carlsbad, California. The company specializes in the discovery and development of precision oncology therapeutics designed to address acquired drug resistance in targeted cancer therapies. Its proprietary SNÅP platform utilizes iterative chemistry approaches to design selective fibroblast growth factor receptor (FGFR) inhibitors. Principal revenue is currently earned through strategic pharmaceutical research collaborations and capital financing arrangements. Tyra Biosciences Inc is publicly listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Tyra Biosciences.
- Legal name
- Tyra Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Tyra Biosciences
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.57 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)